HEXIMA LIMITED

ASX ANNOUNCEMENT

02 November 2021

2021 ANNUAL GENERAL MEETING – CEO'S PRESENTATION

MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) provides the attached CEO Presentation to be delivered at today's Annual General Meeting commencing at 11.00am AEDT.

The AGM can be joined at **https://meetings.linkgroup.com/HXL21**

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO.

Enquiries:
Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please click here

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on Twitter and LinkedIn or email us at info@hexima.com.au.

MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER PRESENTATION

MR MICHAEL ALDRIDGE

hexima

MAJOR ACHIEVEMENTS FY2021

Milestones & Achievements

- Public Offering and listing on ASX
    - $3 million offering at A$0.20 per share
- Phase IIb clinical trial
    - Initiation and completion of enrolment
- Intellectual property protection
- Scientific Advisory Board
    - Australian, US and Japan KOLs

AUSTRALIAN PHASE IIB CLINICAL TRIAL

HXP124-ONY-002



Enrolment completed July 2021

- Multi-center, randomised, double blind, vehicle-controlled study
- Primary endpoint safety and tolerability, secondary endpoints Mycological Cure and Clinical Efficacy
- Three active (2% pezadeftide) versus vehicle arms to test optimal dosing strategy
- Safety & efficacy assessed at 13, 24, 36 and 40 weeks, data expected Q2 2022

HXP124-ONY-002 ANZCTR registration number: ACTRN12620000697987

Strong patent position

ADDITIONAL PROTECTION VIA FORMULATION PATENTS AND MARKET EXCLUSIVITY FOR BIOLOGICS

Clearly defined growth strategy

- Develop independently in US and EU (ICH) markets
- License and collaborative development in Japan and potentially China - presently in preliminary discussions with multiple parties



LOOKING FORWARD

A PIVOTAL YEAR IN GROWTH AND DEVELOPMENT

Expected Milestones

- Ongoing US focused Phase III preparations
  - Completed $11 million financing
- Phase IIb clinical trial – data Q2 2022
- Corporate partnership(s)
- Capital raising to fund phase III
- Expansion of development pipeline
- Initiate Phase III clinical trials - late CY2022

Pezadeftide: a potential solution for a large and poorly served market

POORLY SERVED MARKET

- Affects 14% of the population
- Strong consumer preference for topical products
- Clear unmet medical need

NEW AND UNIQUE

- Novel molecule with unique mode of action
- Strong patent protection and long patent life

SAFE

- No systemic effects
- No local redness or irritation

CONVENIENT

- Easy to apply
- Short treatment duration
- Rapid clearing of infected nail

EFFECTIVE

- Efficiently penetrates the nail
- Rapidly kills fungus
- Best-in-class mycological cure